Data integration and systems biology approaches for biomarker discovery: Challenges and opportunities for multiple sclerosis

Journal of Neuroimmunology

Volumn 248, Issue 1-2, 2012, Pages 58-65

  Villoslada, Pablo ^a   Baranzini, Sergio ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarker; Multiple sclerosis; Network; Omics; Pathway; Systems biology

Indexed keywords

BIOLOGICAL MARKER;

DATA ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; GENE EXPRESSION; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PATIENT SELECTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

ANIMALS; BIOLOGICAL MARKERS; COMPUTATIONAL BIOLOGY; HUMANS; INDIVIDUALIZED MEDICINE; INTERDISCIPLINARY COMMUNICATION; MOLECULAR DIAGNOSTIC TECHNIQUES; MULTIPLE SCLEROSIS; SYSTEMS BIOLOGY; SYSTEMS INTEGRATION;

EID: 84862630197     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.01.001     Document Type: Review

References (57)

1. Auffray C., Charron D., Hood L. Predictive, preventive, personalized and participatory medicine: back to the future. Genome Med. 2010, 2:57.
2. Barabasi A.L., Oltvai Z.N. Network biology: understanding the cell's functional organization. Nat. Rev. Genet. 2004, 5:101-113.
3. Barabasi A.L., Gulbahce N., Loscalzo J. Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 2011, 12:56-68.
4. Baranzini S.E. Systems-based medicine approaches to understand and treat complex diseases. The example of multiple sclerosis. Autoimmunity 2006, 39:651-662.
5. Baranzini S.E., Mousavi P., Rio J., Caillier S.J., Stillman A., Villoslada P., Wyatt M.M., Comabella M., Greller L.D., Somogyi R., Montalban X., Oksenberg J.R. Transcription-based prediction of response to IFNbeta using supervised computational methods. PLoS Biol. 2005, 3:e2.
6. Bejarano B., Bianco M., Gonzalez-Moron D., Sepulcre J., Goni J., Arcocha J., Soto O., Del Carro U., Comi G., Leocani L., Villoslada P. Computational classifiers for predicting the short-term course of multiple sclerosis. BMC Neurol. 2011, 11:67.
7. Bertolotto A., Gilli F. Interferon-beta responders and non-responders. A biological approach. Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. 2008, 29(Suppl. 2):S216-S217.
8. Bertolotto A., Sala A., Malucchi S., Marnetto F., Caldano M., Di Sapio A., Capobianco M., Gilli F. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J. Neurol. Neurosurg. Psychiatry 2004, 75:1294-1299.
9. Bielekova B., Catalfamo M., Reichert-Scrivner S., Packer A., Cerna M., Waldmann T.A., McFarland H., Henkart P.A., Martin R. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5941-5946.
10. Broome T.M., Coleman R.A. A mathematical model of cell death in multiple sclerosis. J. Neurosci. Methods 2011, 201:420-425.
11. Bustamante M.F., Fissolo N., Rio J., Espejo C., Costa C., Mansilla M.J., Lizasoain I., Angeles Moro M., Carmen Edo M., Montalban X., Comabella M. Implication of the toll-like receptor 4 pathway in the response to interferon-beta in multiple sclerosis. Ann. Neurol. 2011, 70:634-645.
12. Carmona-Saez P., Chagoyen M., Tirado F., Carazo J.M., Pascual-Montano A. GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists. Genome Biol. 2007, 8:R3.
13. Conradi C., Saez-Rodriguez J., Gilles E.D., Raisch J. Using chemical reaction network theory to discard a kinetic mechanism hypothesis. Syst. Biol. (Stevenage) 2005, 152:243-248.
14. Corvol J.C., Pelletier D., Henry R.G., Caillier S.J., Wang J., Pappas D., Casazza S., Okuda D.T., Hauser S.L., Oksenberg J.R., Baranzini S.E. Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:11839-11844.
15. Cotsapas C., Voight B.F., Rossin E., Lage K., Neale B.M., Wallace C., Abecasis G.R., Barrett J.C., Behrens T., Cho J., De Jager P.L., Elder J.T., Graham R.R., Gregersen P., Klareskog L., Siminovitch K.A., van Heel D.A., Wijmenga C., Worthington J., Todd J.A., Hafler D.A., Rich S.S., Daly M.J. Pervasive sharing of genetic effects in autoimmune disease. PLoS Genet. 2011, 7:e1002254.
16. Foster K.R. The sociobiology of molecular systems. Nat. Rev. Genet. 2011, 12:193-203.
17. Gilli F. Role of differential expression of interferon receptor isoforms on the response of multiple sclerosis patients to therapy with interferon beta. J. Interferon Cytokine Res. Off. J. Int. Soc. Interferon Cytokine Res. 2010, 30:733-741.
18. Goh K.I., Cusick M.E., Valle D., Childs B., Vidal M., Barabasi A.L. The human disease network. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:8685-8690.
19. Gutierrez-Achury J., Coutinho de Almeida R., Wijmenga C. Shared genetics in coeliac disease and other immune-mediated diseases. J. Intern. Med. 2011, 269:591-603.
20. Hood L., Friend S.H. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat. Rev. Clin. Oncol. 2011, 8:184-187.
21. Ideker T., Sharan R. Protein networks in disease. Genome Res. 2008, 18:644-652.
22. Ioannidis J.P., Panagiotou O.A. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA 2011, 305:2200-2210.
23. Ioannidis J.P., Allison D.B., Ball C.A., Coulibaly I., Cui X., Culhane A.C., Falchi M., Furlanello C., Game L., Jurman G., Mangion J., Mehta T., Nitzberg M., Page G.P., Petretto E., van Noort V. Repeatability of published microarray gene expression analyses. Nat. Genet. 2009, 41:149-155.
24. Killestein J., Polman C.H. Determinants of interferon beta efficacy in patients with multiple sclerosis. Nat. Rev. Neurol. 2011, 7:221-228.
25. Koike F., Satoh J., Miyake S., Yamamoto T., Kawai M., Kikuchi S., Nomura K., Yokoyama K., Ota K., Kanda T., Fukazawa T., Yamamura T. Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis. J. Neuroimmunol. 2003, 139:109-118.
26. Linker R.A., Lee D.H., Ryan S., van Dam A.M., Conrad R., Bista P., Zeng W., Hronowsky X., Buko A., Chollate S., Ellrichmann G., Bruck W., Dawson K., Goelz S., Wiese S., Scannevin R.H., Lukashev M., Gold R. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011, 134:678-692.
27. Lyons P.A., Koukoulaki M., Hatton A., Doggett K., Woffendin H.B., Chaudhry A.N., Smith K.G. Microarray analysis of human leucocyte subsets: the advantages of positive selection and rapid purification. BMC Genomics 2007, 8:64.
28. Ma Q., Lu A.Y. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol. Rev. 2011, 63:437-459.
29. Martinez-Forero I., Pelaez-Lopez A., Villoslada P. Steady state detection of chemical reaction networks using a simplified analytical method. PLoS One 2010, 5:e10823.
30. Martinez-Rodriguez J.E., Lopez-Botet M., Munteis E., Rio J., Roquer J., Montalban X., Comabella M. Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. Clin. Immunol. 2011, 141:348-356.
31. McKinney E.F., Lyons P.A., Carr E.J., Hollis J.L., Jayne D.R., Willcocks L.C., Koukoulaki M., Brazma A., Jovanovic V., Kemeny D.M., Pollard A.J., Macary P.A., Chaudhry A.N., Smith K.G. A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat. Med. 2010, 16:586-591. 581p following 591.
32. Meyer M.R., Maurer H.H. Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics 2011, 12:215-233.
33. Moreno B., Hevia H., Santamaria M., Sepulcre J., Munoz J., Garcia-Trevijano E.R., Berasain C., Corrales F.J., Avila M.A., Villoslada P. Methylthioadenosine reverses brain autoimmune disease. Ann. Neurol. 2006, 60:323-334.
34. Morris M.K., Saez-Rodriguez J., Sorger P.K., Lauffenburger D.A. Logic-based models for the analysis of cell signaling networks. Biochemistry 2010, 49:3216-3224.
35. Muraro P.A., Liberati L., Bonanni L., Pantalone A., Caporale C.M., Iarlori C., De Luca G., Farina D., Lugaresi A., Gambi D. Decreased integrin gene expression in patients with MS responding to interferon-beta treatment. J. Neuroimmunol. 2004, 150:123-131.
36. Nogales-Cadenas R., Carmona-Saez P., Vazquez M., Vicente C., Yang X., Tirado F., Carazo J.M., Pascual-Montano A. GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information. Nucleic Acids Res. 2009, 37:W317-W322.
37. Palacios R., Goni J., Martinez-Forero I., Iranzo J., Sepulcre J., Melero I., Villoslada P. A network analysis of the human T-cell activation gene network identifies JAGGED1 as a therapeutic target for autoimmune diseases. PLoS One 2007, 2:e1222.
38. Platten M., Ho P.P., Youssef S., Fontoura P., Garren H., Hur E.M., Gupta R., Lee L.Y., Kidd B.A., Robinson W.H., Sobel R.A., Selley M.L., Steinman L. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 2005, 310:850-855.
39. Saez-Rodriguez J., Simeoni L., Lindquist J.A., Hemenway R., Bommhardt U., Arndt B., Haus U.U., Weismantel R., Gilles E.D., Klamt S., Schraven B. A logical model provides insights into T cell receptor signaling. PLoS Comput. Biol. 2007, 3:e163.
40. Saez-Rodriguez J., Alexopoulos L.G., Epperlein J., Samaga R., Lauffenburger D.A., Klamt S., Sorger P.K. Discrete logic modelling as a means to link protein signalling networks with functional analysis of mammalian signal transduction. Mol. Syst. Biol. 2009, 5:331.
41. Schadt E.E., Friend S.H., Shaywitz D.A. A network view of disease and compound screening. Nat. Rev. Drug Discov. 2009, 8:286-295.
42. Sellebjerg F., Datta P., Larsen J., Rieneck K., Alsing I., Oturai A., Svejgaard A., Soelberg Sorensen P., Ryder L.P. Gene expression analysis of interferon-beta treatment in multiple sclerosis. Mult. Scler. 2008, 14:615-621.
43. Sellebjerg F., Krakauer M., Hesse D., Ryder L.P., Alsing I., Jensen P.E., Koch-Henriksen N., Svejgaard A., Soelberg Sorensen P. Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. Eur. J. Neurol. Off. J. Eur. Fed. Neurol. Soc. 2009, 16:1291-1298.
44. Sieberts S.K., Schadt E.E. Moving toward a system genetics view of disease. Mamm. Genome 2007, 18:389-401.
45. Sturzebecher S., Wandinger K.P., Rosenwald A., Sathyamoorthy M., Tzou A., Mattar P., Frank J.A., Staudt L., Martin R., McFarland H.F. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain J. Neurol. 2003, 126:1419-1429.
46. Tumani H., Hartung H.P., Hemmer B., Teunissen C., Deisenhammer F., Giovannoni G., Zettl U.K. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol. Dis. 2009, 35:117-127.
47. van Baarsen L.G., Vosslamber S., Tijssen M., Baggen J.M., van der Voort L.F., Killestein J., van der Pouw Kraan T.C., Polman C.H., Verweij C.L. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One 2008, 3:e1927.
48. van der Greef J., Martin S., Juhasz P., Adourian A., Plasterer T., Verheij E.R., McBurney R.N. The art and practice of systems biology in medicine: mapping patterns of relationships. J. Proteome Res. 2007, 6:1540-1559.
49. Velez de Mendizabal N., Carneiro J., Sole R.V., Goni J., Bragard J., Martinez-Forero I., Martinez-Pasamar S., Sepulcre J., Torrealdea J., Bagnato F., Garcia-Ojalvo J., Villoslada P. Modeling the effector - regulatory T cell cross-regulation reveals the intrinsic character of relapses in Multiple Sclerosis. BMC Syst. Biol. 2011, 5:114.
50. Villoslada P. Biomarkers for multiple sclerosis. Drug News Perspect. 2010, 23:585-595.
51. Villoslada P., Oksenberg J. Neuroinformatics in clinical practice: are computers going to help neurological patients and their physicians?. Future Neurol. 2006, 1:1-12.
52. Villoslada P., Steinman L., Baranzini S.E. Systems biology and its application to the understanding of neurological diseases. Ann. Neurol. 2009, 65:124-139.
53. Wandinger K.P., Sturzebecher C.S., Bielekova B., Detore G., Rosenwald A., Staudt L.M., McFarland H.F., Martin R. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann. Neurol. 2001, 50:349-357.
54. Wandinger K.P., Lunemann J.D., Wengert O., Bellmann-Strobl J., Aktas O., Weber A., Grundstrom E., Ehrlich S., Wernecke K.D., Volk H.D., Zipp F. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003, 361:2036-2043.
55. Wang L., Khankhanian P., Baranzini S.E., Mousavi P. iCTNet: a Cytoscape plugin to produce and analyze integrative complex traits networks. BMC Bioinform. 2011, 12:380.
56. Warner A.W., Bhathena A., Gilardi S., Mohr D., Leong D., Bienfait K.L., Sarang J., Duprey S., Franc M.A., Nelsen A., Snapir A. Challenges in obtaining adequate genetic sample sets in clinical trials: the perspective of the industry pharmacogenomics working group. Clin. Pharmacol. Ther. 2011, 89:529-536.
57. Zhernakova A., van Diemen C.C., Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat. Rev. Genet. 2009, 10:43-55.